Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?

Eur Heart J. 2008 Apr;29(7):915-22. doi: 10.1093/eurheartj/ehn101. Epub 2008 Mar 10.

Abstract

Aims: To assess the relation between the atrial fibrillation (AF) subtype and thrombo-embolic events.

Methods and results: The observational Euro Heart Survey on AF (2003-04) enrolled 1509 paroxysmal, 1109 persistent, and 1515 permanent AF patients, according to the 2001 American College of Cardiology, American Heart Association, and the European Society of Cardiology guidelines definitions. A 1 year follow-up was performed. Permanent AF patients had at baseline a worse stroke risk profile than paroxysmal and persistent AF patients. In paroxysmal AF, the risk for stroke, any thrombo-embolism, major bleeding and the combined endpoint of cardiovascular mortality, any thrombo-embolism, and major bleeding was comparable with persistent and permanent AF, in both univariable and multivariable analyses. Compared with AF patients without stroke, patients suffering from a stroke had a comparable frequency and duration of AF attacks, but tended to have a worse stroke risk profile at baseline. During 1 year following cardioversion, paroxysmal AF patients had a higher risk for stroke (P = 0.029) and any thrombo-embolism (P = 0.001) than persistent AF patients.

Conclusion: In the Euro Heart Survey, paroxysmal AF had a comparable risk for thrombo-embolic events as persistent and permanent AF. This observation strengthens the guideline recommendation not to consider the clinical AF subtype when deciding on anticoagulation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Anticoagulants / administration & dosage*
  • Aspirin / administration & dosage*
  • Atrial Fibrillation / complications*
  • Atrial Fibrillation / therapy
  • Electric Countershock / adverse effects
  • Electrocardiography
  • Female
  • Fibrinolytic Agents / administration & dosage*
  • Follow-Up Studies
  • Humans
  • Male
  • Risk Factors
  • Stroke / etiology
  • Stroke / prevention & control*
  • Treatment Outcome
  • Withholding Treatment

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Aspirin